Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study
Fabrizia Mariotti (Parma, Italy), Sara Collarini, Anna Compagnoni, Dario Cuomo, Fabrizia Mariotti, Annamaria Muraro, Daniela Acerbi
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Fabrizia Mariotti (Parma, Italy), Sara Collarini, Anna Compagnoni, Dario Cuomo, Fabrizia Mariotti, Annamaria Muraro, Daniela Acerbi. Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study. Eur Respir J 2015; 46: Suppl. 59, 2961
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Source: Eur Respir J 2002; 20: 1138-1146 Year: 2002
A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Source: ERJ Open Res 2016: 00101-2015 Year: 2016
A multicentre, double-blind, double-dummy, randomized, parallel group study to assess efficacy and safety of beclomethasone dipropionate and ease of handling of a breath operated aerosol inhaler in adults with reversible airways obstruction Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016
Long-term safety of twice-daily aclidinium bromide in COPD patients: A one-year, double-blind study Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
A multi-centre, randomised, cross-over study to investigate therapy adherence with and preference for inhaled maintenance therapy via separate Diskus versus a combination product in one Diskus Source: Eur Respir J 2002; 20: Suppl. 38, 448s Year: 2002
Glycopyrronium does not affect QT interval in healthy subjects: A randomized, 3-period cross-over, placebo- and positive-controlled study Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Treatment of asthmatic patients with beclomethason dipropionate (BDP) or budesonide(B)-comparative, randomized, double blind clinical study Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009